These are links to recent news stories that may be of interest to people in the UK. Click on the link beneath each item to be taken to the original story.
Please note that the MS Trust did not write the original items and does not endorse their content nor any claims made in them.
To keep up to date on all the latest news, views and research on multiple sclerosis, sign up for Open Door, our free newsletter.
Cladribine comeback planned
Based on "new data and additional analyses of the compound’s benefit-risk profile", Merck is planning to submit cladribine to the EMA, the European drug regulator, for licensing. The development of the drug was stopped in 2011 following potential cancer risks
MS Trust link: Cladribine - A to Z of MS